自身免疫性肝炎大鼠血清IL-38和β2GPI水平及其与肝组织病变的关系*

doi:10.3969/j.issn.1672-5069.2021.06.009

Abstract

Abstract: Objective The aim of this study was to serum interleukin-38 (IL-38) and β2 glycoprotein I(β2GPI) levels in rats with autoimmune hepatitis (AIH) and their relationship with liver tissue lesions. Methods The AIH model was established by liver-specific lipoprotein and complete Freund' s adjuvant intraperitoneal injection. The liver tissues was obtained for phthological examination, and serum IL-38 and β2GPI levels were detected by ELISA. Results SerumIL-38 level in 8 AIH rats with severe hepatic injuries was (63.8±9.5)pg/ml, significantly lower than in 17 rats with mild or 15 rats with moderate hepatic injuries [(100.3±16.9)pg/ml and (85.1±11.3)pg/ml, respectively, P<0.05), while serum β2GPI level was (4005.9±428.6)μg/L, significantly higher than in rats with mild or moderate hepatic injuries [(2752.1±310.9)μg/L and (3190.5±362.7)μg/L, respectively, P<0.05]; serum IL-38 level in 6 rats with hepatic vascular lesion grade 3 was (39.5±6.9)pg/ml, significantly lower than in 18 rats with grade 1 or 16 rats with grade 2 hepatic vascular lesions [(102.1±17.2)pg/ml and (88.4±11.5)pg/ml, respectively, P<0.05], while serum β2GPI level was (3866.3±401.7)μg/L, much higher than in rats with grade 1 or 2 [(2779.3±309.0)μg/L and (3341.5±370.2)μg/L, respectively, P<0.05]. Conclusion Serum IL-38 levels decrease, while serum β2GPI levels increase with the deterioration of liver tissue injuries in rats with AIH, and the balance of the two cytokines might take part in the pathogenesis of AIH, which needs further investigation.

Key words: Autoimmune hepatitis, Interleukin-38, β2 glycoprotein I, Liver vascular lesions, Rats

Shi Xueli, Zhang Wanli, Mao Jun. Serum IL-38 and β2GPI levels in rats with autoimmune hepatitis and their relationship with liver tissue lesions[J]. Journal of Practical Hepatology, 2021, 24(6): 803-806.

References

[1] Kerkar N, Chan A. Autoimmune hepatitis, sclerosing cholangitis, and autoimmune sclerosing cholangitis or overlap syndrome. Clin Liver Dis, 2018, 22(4):689-702.
[2] Sebode M, Hartl J, Vergani D, et al. Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. Liver Int, 2018, 38(1):15-22.
[3] HayatDavoudi G, Makvandi M, Teimoori A, et al. Frequency of OBI among patients with autoimmune hepatitis. Asian Pac J Cancer Prev, 2020, 21(9):2555-2559.
[4] van deVeerdonk FL, de Graaf DM, Joosten LA, et al. Biology of IL-38 and its role in disease. Immunol Rev, 2018, 281(1):191-196.
[5] Xu WD, Su LC, Liu XY, et al. IL-38: A novel cytokine in systemic lupus erythematosus pathogenesis. J Cell Mol Med, 2020, 24(21):12379-12389.
[6] Jing X,Tian Z, Gao P, et al. HBsAg/β2GPI activates the NF κB pathway via the TLR4/MyD88/IκBα axis in hepatocellular carcinoma. Oncol Rep, 2018, 40(2):1035-1045.
[7] Petri M. Improvements in diagnosis and risk assessment of primary and secondaryantiphospholipid syndrome. Hematology Am Soc Hematol Educ Program, 2019, 2019(1):415-420.
[8] Benagiano M, Borghi MO, Romagnoli J, et al. Interleukin-17/Interleukin-21 and Interferon-γ producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. Haematologica, 2019, 104(12):2519-2527.
[9] Aljumah AA, Al Jarallah B, Albenmousa A, et al. The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis. Saudi J Gastroenterol, 2018, 24(l):1-20.
[10] 王莉,李家斌,马勇,等.脂多糖在慢性乙型肝炎肝内血管病变中的作用.实用肝脏病杂志,2012,15(1):14-17.
[11] Czaja AJ. Under-evaluated or unassessed pathogenic pathways in autoimmune hepatitis and implications for future management. Dig Dis Sci, 2018, 63(7):1706-1725.
[12] 彭小燕,徐莉娟,刘鹏,等.自身免疫性肝炎患者血清腺苷脱氨酶水平与肝组织炎症活动程度的关系及对治疗应答的影响.实用肝脏病杂志,2019,22(2):200-203.
[13] Wang QX, Yan L, Ma X. Autoimmunehepatitis in the Asia-Pacific area. J Clin Transl Hepatol, 2018, 6(1):48-56.
[14] Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity, 2013, 39(6):1003-1018.
[15] Mora J,Schlemmer A, Wittig I, et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol, 2016, 8(5):426-438.
[16] Xie L, Huang Z, Li H, et al. IL-38: A new player in inflammatory autoimmune disorders. Biomolecules, 2019, 9(8):345-367.
[17] Virachith S, Saito M, Watanabe Y, et al. Anti-β2 -glycoprotein I antibody with DNA binding activity enters living monocytes via cell surface DNA and induces tissue factor expression. Clin Exp Immunol, 2019, 195(2):167-178.
[18] Colasanti T, Alessandri C, Capozzi A, et al. Autoantibodies specific to a peptide of β2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes. Blood, 2012, 120(16):3360-3370.
[19] Ruben E, Planer W,Chinnaraj M, et al. The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. J Biol Chem, 2020, 295(31):10794-10806.
[20] Liu YM, Zhang WY, Wang ZF,et al. High expression of beta2-glycoprotein I is associated significantly with the earliest stages of hepatitis B virus infection. J Med Virol, 2014, 86(8):1296-1306.
[21] Wang H, Wang X, Zhang M, et al. Beta2-glycoprotein I in hepatitis B virus infection patients with hepatocellular carcinoma, chronic hepatitis B and acute hepatitis B. Int J Clin Exp Med, 2016, 9(10):10846-10852.

Serum IL-38 and β2GPI levels in rats with autoimmune hepatitis and their relationship with liver tissue lesions

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Gu Xuexiang, Li Xiangyu, Shan Qinxing. Protective effect of saikosaponin A on hepatic steatosis in rats with non-alcoholic fatty liver disease by affecting PPARα signaling pathway [J]. Journal of Practical Hepatology, 2021, 24(6): 807-810.
[2]	Xiao Jinyu, Wang Yanfeng, Wen Xiaoxia. Serum chemokines CCL4 and CXCL10 levels in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(6): 827-830.
[3]	Wang Qixia, Ma Xiong. Insights to precision medicine and clinical translational research in patients with autoimmune liver diseases [J]. Journal of Practical Hepatology, 2021, 24(4): 457-459.
[4]	Li Bianli, Xu Lihong. Differential diagnosis of drug-induced liver injury, drug-induced autoimmune hepatitis and autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 460-463.
[5]	Liang Yuping, Su Quanqiu, Zhang Hui, et al. Serum vitamin D deficiency in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 464-467.
[6]	Liu Na, Zhang Huamin, Deng Qiaojuan. Impact of inhibition of TRAF6 gene expression on hepatic NF-κB-related protein expression in rats with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 468-471.
[7]	Qi Mei, Zhang Ruijin, Tian Shuping, et al. Impacting factors in response to immunosuppressive therapy in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 371-374.
[8]	Rong Haifang, Wang Liguo. Establishment of hepatopulmonary syndrome induced by common bile duct ligation in rats [J]. Journal of Practical Hepatology, 2021, 24(2): 176-179.
[9]	Su Qihao, Ren Limei, Jiang Fengxia, et al. Protective effect of Mongolian medicine Erligen II on liver fibrosis in rats [J]. Journal of Practical Hepatology, 2021, 24(2): 180-183.
[10]	Nie Liu, Peng Hanming, Liao Dongliang. Combination of ursodeoxycholic acid and prednisone and azathioprine in the treatment of patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(2): 224-227.
[11]	Rong Aimei,Zhang Chao,Wu Huili. Effect of sirolimus on peripheral blood Treg/Th17 cell ratio in high fat diet-induced NAFLD in rats [J]. Journal of Practical Hepatology, 2021, 24(1): 10-13.
[12]	Li Qingling, He Shuguang, Yi Xiaoming, et al. Changes of peripheral blood lymphocyte PD-1 and PD-L1 expression in patients with autoimmune hepatitis receiving tripterygium wilfordii polyglycosides and magnesium iso-glycyrrhizate [J]. Journal of Practical Hepatology, 2021, 24(1): 79-82.
[13]	Li Wei, Guo Chunxia, Liu Sunan. Increasedliver regeneration and liver tissue NK cell cytoxicity by resveratrol stimulus in rats with partial hepatectomy [J]. Journal of Practical Hepatology, 2020, 23(6): 785-788.
[14]	Wang Yu, Wang Nan, Wang Qiaoxia, et al. Liganlong and magnesium isoglycyrrhizate combination mitigates liver injury via inhibiting humoral immunity in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2020, 23(6): 821-824.
[15]	Ling Jing, Zhang Youjian, Song Xiongfeng. Changes of serum chemokines and GP73levels in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2020, 23(6): 825-828.